| Active ingredients | Dosage form | Quantity of active ingredients | Shortage status | Availability | Reason | Last updated |
| dutasteride~tamsulosin hydrochloride | Capsule, modified release | 500 microgram~400 microgram | Anticipated | Available | Transport / Logistic issues / Storage capacity issues | 22/09/2024 |
| gabapentin | Capsule, hard | 300 mg | Current | Limited Availability | Manufacturing | 20/09/2024 |
| sumatriptan succinate | Tablet, film coated | 140 mg | Current | Limited Availability | Manufacturing | 20/09/2024 |
| venlafaxine | Capsule, modified release | 75 mg | Current | Limited Availability | Manufacturing | 20/09/2024 |
| venlafaxine | Capsule, modified release | 150 mg | Current | Limited Availability | Manufacturing | 20/09/2024 |
| Filgrastim | Injection, solution | 120 microgram | Resolved | Available | Transport / Logistic issues / Storage capacity issues | 20/09/2024 |
| Filgrastim | Injection, solution | 480 microgram | Resolved | Available | Transport / Logistic issues / Storage capacity issues | 20/09/2024 |
| duloxetine hydrochloride | Capsule, enteric | 67.3 mg | Current | Limited Availability | Manufacturing | 20/09/2024 |
| duloxetine hydrochloride | Capsule, enteric | 33.66 mg | Current | Unavailable | Unexpected increase in consumer demand | 20/09/2024 |
| fenofibrate | Tablet | 48 mg | Anticipated | Available | Manufacturing | 20/09/2024 |
| buprenorphine | Drug delivery system, transdermal | 40 mg | Anticipated | Available | Transport / Logistic issues / Storage capacity issues | 20/09/2024 |
| emtricitabine~tenofovir disoproxil fumarate | Tablet, film coated | 200 mg~300 mg | Current | Unavailable | Manufacturing | 20/09/2024 |
| trimethoprim | Tablet, uncoated | 300 mg | Anticipated | Available | Manufacturing | 20/09/2024 |
| lenalidomide | Capsule, hard | 5 mg | Current | Limited Availability | Unexpected increase in consumer demand | 20/09/2024 |
| lanreotide acetate | Injection, solution | 133.33 mg | Current | Unavailable | Transport / Logistic issues / Storage capacity issues | 20/09/2024 |
| rosuvastatin calcium~ezetimibe | Tablet~Tablet, film coated | 41.6 mg~10 mg | Current | Limited Availability | Manufacturing | 20/09/2024 |
| rosuvastatin calcium~ezetimibe | Tablet~Tablet, film coated | 20.8 mg~10 mg | Current | Unavailable | Manufacturing | 20/09/2024 |
| fluticasone propionate | Inhalation, pressurised | 125 microgram/actuation | Current | Limited Availability | Unexpected increase in consumer demand | 20/09/2024 |
| clindamycin phosphate | Lotion | 10 mg/mL | Current | Limited Availability | Manufacturing | 20/09/2024 |
| Epoetin lambda | Injection, solution | 10000 IU | Resolved | Available | Manufacturing | 19/09/2024 |
| omeprazole | Capsule | 20 mg | Resolved | Available | Manufacturing | 19/09/2024 |
| insulin | Injection, solution | 100 IU/mL | Discontinued | Reduction in supply until supply is exhausted | Commercial Changes / Commercial viability | 19/09/2024 |
| insulin | Injection, suspension | 100 IU/mL | Discontinued | Reduction in supply until supply is exhausted | Commercial Changes / Commercial viability | 19/09/2024 |
| insulin | Injection, suspension | 100 IU/mL | Discontinued | Reduction in supply until supply is exhausted | Commercial Changes / Commercial viability | 19/09/2024 |
| Insulin detemir | Injection, solution | 100 U/mL | Discontinued | Reduction in supply until supply is exhausted | Commercial Changes / Commercial viability | 19/09/2024 |
| Insulin detemir | Injection, solution | 100 U/mL | Discontinued | Reduction in supply until supply is exhausted | Commercial Changes / Commercial viability | 19/09/2024 |
| bisoprolol fumarate | Tablet | 10 mg | Anticipated | Available | Manufacturing | 19/09/2024 |
| montelukast sodium | Tablet, chewable | 5.2 mg | Current | Unavailable | Manufacturing | 19/09/2024 |
| quetiapine fumarate | Tablet, film coated | 28.784 mg | Resolved | Available | Unexpected increase in consumer demand | 19/09/2024 |
| paclitaxel | Injection, concentrated | 300 mg | Current | Unavailable | Manufacturing | 19/09/2024 |
| cisatracurium besilate | Injection, solution | 201 mg | Discontinued | Unavailable | Manufacturing | 19/09/2024 |
| Follitropin alfa | Injection, solution | 75 IU | Anticipated | Available | Manufacturing | 19/09/2024 |
| Follitropin alfa | Injection, solution | 150 IU | Anticipated | Available | Manufacturing | 19/09/2024 |
| fluticasone propionate | Inhalation, pressurised | 125 microgram/actuation | Current | Unavailable | Manufacturing | 19/09/2024 |
| Insulin aspart | Injection, solution | 100 U/mL | Discontinued | Reduction in supply until supply is exhausted | Commercial Changes / Commercial viability | 19/09/2024 |
| Insulin aspart | Injection, solution | 100 U/mL | Discontinued | Reduction in supply until supply is exhausted | Commercial Changes / Commercial viability | 19/09/2024 |
| Insulin degludec~Insulin aspart | Injection, solution | 420 nmol/mL~180 nmol/mL | Discontinued | Reduction in supply until supply is exhausted | Commercial Changes / Commercial viability | 19/09/2024 |
| gliclazide | Tablet, modified release | 30 mg | Current | Limited Availability | Unexpected increase in demand due to other sponsors unable to supply | 19/09/2024 |
| atorvastatin calcium trihydrate~ezetimibe | Tablet, film coated | 82.725 mg~10 mg | Current | Unavailable | Manufacturing | 19/09/2024 |
| atorvastatin calcium trihydrate~ezetimibe | Tablet, film coated | 41.363 mg~10 mg | Current | Unavailable | Manufacturing | 19/09/2024 |
| lurasidone hydrochloride | Tablet, film coated | 80 mg | Current | Unavailable | Manufacturing | 19/09/2024 |
| olmesartan medoxomil~amlodipine besilate | Tablet, film coated | 40 mg~6.94 mg | Current | Limited Availability | Unexpected increase in consumer demand | 19/09/2024 |
| methylphenidate hydrochloride | Tablet, modified release | 18 mg | Current | Unavailable | Manufacturing | 19/09/2024 |
| levothyroxine sodium | Tablet, uncoated | .1 mg | Current | Unavailable | Manufacturing | 19/09/2024 |
| levothyroxine sodium | Tablet, uncoated | .2 mg | Current | Limited Availability | Manufacturing | 19/09/2024 |
| Dornase alfa | Spray, solution | 1 mg/mL | Resolved | Available | Commercial Changes / Commercial viability | 19/09/2024 |
| dorzolamide hydrochloride | Eye Drops, solution | 22.26 mg/mL | Anticipated | Available | Manufacturing | 19/09/2024 |
| captopril | Tablet, uncoated | 50 mg | Current | Unavailable | Manufacturing | 19/09/2024 |
| clindamycin hydrochloride | Solution | 10 mg/mL | Current | Unavailable | Manufacturing | 19/09/2024 |
| amoxicillin sodium | Injection, powder for | 1060 mg | Current | Limited Availability | Manufacturing | 19/09/2024 |
| amoxicillin trihydrate | Oral Liquid, powder for | 114.82 mg/mL | Current | Unavailable | Manufacturing | 19/09/2024 |
| tacrolimus monohydrate | Capsule, hard | 1.022 mg | Anticipated | Available | Manufacturing | 18/09/2024 |
| carmustine | Injection, powder for | 100 mg | Resolved | Available | Manufacturing | 18/09/2024 |
| dulaglutide | Injection, solution | 1.5 mg | Current | Limited Availability | Manufacturing | 18/09/2024 |
| adrenaline (epinephrine) acid tartrate | Injection, solution | 1.819 mg | Resolved | Available | Manufacturing | 18/09/2024 |
| spironolactone | Tablet, uncoated | 100 mg | Current | Limited Availability | Manufacturing | 18/09/2024 |
| chloramphenicol | Eye Drops, solution | 5 mg/mL | Current | Unavailable | Manufacturing | 18/09/2024 |
| sitagliptin fumarate | Tablet, film coated | 128.497 mg | Resolved | Available | Unexpected increase in demand due to other sponsors unable to supply | 18/09/2024 |
| indometacin | Capsule, hard | 25 mg | Current | Unavailable | Manufacturing | 18/09/2024 |
| captopril | Tablet, uncoated | 25 mg | Current | Unavailable | Manufacturing | 18/09/2024 |
| estradiol~norethisterone acetate | Drug delivery system, transdermal | .62 mg~2.7 mg | Current | Unavailable | Manufacturing | 18/09/2024 |
| ciprofloxacin hydrochloride | Tablet, film coated | 873.32 mg | Anticipated | Available | Manufacturing | 18/09/2024 |
| norethisterone | Tablet, uncoated | 350 microgram | Current | Unavailable | Manufacturing | 17/09/2024 |
| isosorbide dinitrate | Tablet, uncoated | 5 mg | Anticipated | Available | Manufacturing | 17/09/2024 |
| codeine phosphate hemihydrate~ibuprofen | Tablet, film coated | 12.8 mg~200 mg | Current | Unavailable | Transport / Logistic issues / Storage capacity issues | 17/09/2024 |
| simvastatin | Tablet, film coated | 20 mg | Anticipated | Available | Manufacturing | 17/09/2024 |
| tenofovir disoproxil maleate~emtricitabine | Tablet, film coated | 300 mg~200 mg | Current | Unavailable | Manufacturing | 17/09/2024 |
| atorvastatin calcium trihydrate~ezetimibe | Tablet, film coated | 10.341 mg~10 mg | Anticipated | Available | Manufacturing | 17/09/2024 |
| zolpidem tartrate | Tablet, film coated | 10 mg | Anticipated | Available | Manufacturing | 16/09/2024 |
| medronic acid | Injection, powder for | 10 mg | Anticipated | Available | Manufacturing | 16/09/2024 |
| gabapentin | Tablet, film coated | 600 mg | Resolved | Available | Manufacturing | 16/09/2024 |
| adrenaline (epinephrine) | Injection, solution | 1 mg | Current | Limited Availability | Unexpected increase in demand due to other sponsors unable to supply | 16/09/2024 |
| levetiracetam | Tablet, film coated | 1000 mg | Current | Unavailable | Transport / Logistic issues / Storage capacity issues | 16/09/2024 |
| noradrenaline (norepinephrine) acid tartrate monohydrate | Injection, concentrated | 2 mg/mL | Discontinued | Reduction in supply until supply is exhausted | Commercial Changes / Commercial viability | 16/09/2024 |
| oseltamivir phosphate | Oral Liquid, powder for | 7.88 mg/mL | Resolved | Available | Unexpected increase in consumer demand | 16/09/2024 |
| azithromycin dihydrate | Tablet, film coated | 524.05 mg | Current | Unavailable | Manufacturing | 16/09/2024 |
| quetiapine fumarate | Tablet, film coated | 345.36 mg | Current | Limited Availability | Manufacturing | 16/09/2024 |
| irbesartan | Tablet, film coated | 300 mg | Anticipated | Available | Manufacturing | 16/09/2024 |
| rizatriptan benzoate | Tablet, orally disintegrating | 14.53 mg | Current | Unavailable | Manufacturing | 16/09/2024 |
| olmesartan medoxomil | Tablet, film coated | 40 mg | Anticipated | Available | Manufacturing | 16/09/2024 |
| olmesartan medoxomil~hydrochlorothiazide | Tablet, film coated | 40 mg~25 mg | Anticipated | Available | Manufacturing | 16/09/2024 |
| azacitidine | Injection, powder for | 100 mg | Current | Limited Availability | Manufacturing | 16/09/2024 |
| anastrozole | Tablet, film coated | 1 mg | Anticipated | Available | Manufacturing | 16/09/2024 |
| irbesartan | Tablet, film coated | 150 mg | Current | Unavailable | Manufacturing | 16/09/2024 |
| tadalafil | Tablet | 5 mg | Current | Unavailable | Unexpected increase in demand due to other sponsors unable to supply | 16/09/2024 |
| tadalafil | Tablet, film coated | 5 mg | Current | Unavailable | Manufacturing | 16/09/2024 |
| nebivolol hydrochloride | Tablet | 5.45 mg | Anticipated | Available | Manufacturing | 16/09/2024 |
| tadalafil | Tablet, film coated | 5 mg | Current | Unavailable | Manufacturing | 16/09/2024 |
| tadalafil | Tablet, film coated | 5 mg | Current | Unavailable | Manufacturing | 16/09/2024 |
| tadalafil | Tablet, film coated | 5 mg | Current | Unavailable | Manufacturing | 16/09/2024 |
| tadalafil | Tablet, film coated | 5 mg | Current | Unavailable | Unexpected increase in demand due to other sponsors unable to supply | 16/09/2024 |
| amlodipine besilate~olmesartan medoxomil | Tablet, film coated | 6.935 mg~40 mg | Current | Unavailable | Manufacturing | 16/09/2024 |
| lacosamide | Tablet, film coated | 150 mg | Anticipated | Available | Manufacturing | 16/09/2024 |
| ezetimibe~atorvastatin calcium trihydrate | Tablet, film coated | 10 mg~10.341 mg | Current | Unavailable | Manufacturing | 16/09/2024 |
| lenalidomide | Capsule | 5 mg | Discontinued | Reduction in supply until supply is exhausted | Commercial Changes / Commercial viability | 16/09/2024 |
| lenalidomide | Capsule | 10 mg | Discontinued | Reduction in supply until supply is exhausted | Commercial Changes / Commercial viability | 16/09/2024 |
| lenalidomide | Capsule | 15 mg | Discontinued | Reduction in supply until supply is exhausted | Commercial Changes / Commercial viability | 16/09/2024 |
| lenalidomide | Capsule | 25 mg | Discontinued | Reduction in supply until supply is exhausted | Commercial Changes / Commercial viability | 16/09/2024 |
| gefitinib | Tablet, film coated | 250 mg | Current | Unavailable | Manufacturing | 16/09/2024 |
| methotrexate | Tablet | 10 mg | Anticipated | Available | Manufacturing | 16/09/2024 |
| heparin sodium | Injection, solution | 1000 IU/mL | Current | Unavailable | Manufacturing | 16/09/2024 |
| doxorubicin hydrochloride | Injection, concentrated | 2 mg/mL | Current | Unavailable | Manufacturing | 16/09/2024 |
2024年9月24日